Medicilon (Chuansha) Inc. won the "Development Potential Award" of Chuansha New Town

On March 20, Chuansha New Town grandly held the 2024 Enterprise Commendation Event and Investment Promotion Launching Ceremony. At the meeting, Medicilon (Chuansha) Inc., a subsidiary of Shanghai Medicilon Inc. (Medicilon), relied on its outstanding performance and strong development momentum in the field of biopharmaceutical, won the "Development Potential Award" for the 2023 Chuansha New Town Economic Work Advanced Unit.

Development Potential Award.webp

As a one-stop biopharmaceutical preclinical R&D service platform, Medicilon is well-deserved for the award. Over the past two decades, Medicilon has been deeply involved in the field of biopharmaceutical preclinical research and development. Medicilon has not only continue to shine in the field of traditional chemical drugs, but also proactively planning ahead in emerging tracks such as bi/multi-specific antibodies, ADCs, PROTACs, mRNA vaccines, small nucleic acid drugs, cells and immunity, and have built a series of efficient and cutting-edge technology service platforms. By the end of 2023, Medicilon has participated in the research and development of 421 new drugs and generic drug projects that have been approved for clinical use.

Winning the "Development Potential Award" this time is not only an affirmation of Medicilon's own empowerment achievements in the past year, but also recognition of its future development potential. In the future, Medicilon will continue to take technological innovation as the driving force, keep up with industry development trends, explore more cutting-edge technologies, continue to innovate and improve the R&D service platform, and inject continuous innovative vitality into the vigorous development of the biopharmaceutical industry!

此博客中的热门博文

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客